Restricted accessResearch articleFirst published online 2015-04
Comorbid Anxiety and Social Avoidance in Treatment of Severe Childhood Aggression: Response to Adding Risperidone to Stimulant and Parent Training;Mediation of Disruptive Symptom Response
In the four-site Treatment of Severe Childhood Aggression (TOSCA) study, addition of risperidone to stimulant and parent training moderately improved parent-rated disruptive behavior disorder (DBD) symptoms. This secondary study explores outcomes other than DBD and attention-deficit/hyperactivity disorder (ADHD) as measured by the Child and Adolescent Symptom Inventory-4R (CASI-4R).
Methods:
A total of 168 children ages 6–12 with severe aggression (physical harm), DBD, and ADHD were randomized to parent training plus stimulant plus placebo (basic treatment) or parent training plus stimulant plus risperidone (augmented treatment) for 9 weeks. All received only parent training plus stimulant for the first 3 weeks, then those with room for improvement received a second drug (placebo or risperidone) for 6 weeks. CASI-4R category item means at baseline and week 9 were entered into linear mixed-effects models for repeated measures to evaluate group differences in changes. Mediation of the primary DBD outcome was explored.
Results:
Parent ratings were nonsignificant with small/negligible effects, but teacher ratings (n=46 with complete data) showed significant augmented treatment advantage for symptoms of anxiety (p=0.013, d=0.71), schizophrenia spectrum (p=0.017, d=0.45), and impairment in these domains (p=0.02, d=0.26), all remaining significant after false discovery rate correction for multiple tests. Improvement in teacher-rated anxiety significantly (p=0.001) mediated the effect of risperidone augmentation on the primary outcome, the Disruptive-total of the parent-rated Nisonger Child Behavior Rating Form.
Conclusions:
Addition of risperidone to parent training plus stimulant improves not only parent-rated DBD as previously reported, but also teacher-rated anxiety–social avoidance. Improvement in anxiety mediates improvement in DBD, suggesting anxiety-driven fight-or-flight disruptive behavior with aggression, with implications for potential treatment strategies. Clinicians should attend to possible anxiety in children presenting with aggression and DBD.
Clinical Trial Registry:
Treatment of Severe Childhood Aggression (The TOSCA Study). NCT00796302. clinicaltrials.gov.
Get full access to this article
View all access options for this article.
References
1.
AmanM: Psychoactive drugs in mental retardation. In: Treatment Issues and Innovations in Mental Retardation, edited by MatsonJ.L. and AndrasikF.. New York: Plenum Press, 455–505, 1983.
2.
AmanM, BuksteinO, GadowK, ArnoldL, MolinaS, McNamaraN, Rundberg-RiveraE, LiX, KippH, SchneiderJ, ButterE, BakerJ, SprafkinJ, RiceR, BangaloreS, FarmerC, AustinA, Buchan-PageK, BrownN, HurtE, GrondhuisS, FindlingR: What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder: J Am Acad Child Adolesc Psychiatry, 53:47–60, 2014.
3.
AmanM, LeoneS, LecavalierL, ParkL, BuicanB, CouryD: The Nisonger child behavior rating form: Typical IQ version, for children with typical IQ. Int Clin Psychopharmacol, 23:232–242, 2008.
4.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
5.
ArnoldL, AmanM: Beta blockers in mental retardation and developmental disorders. J Child Adolesc Psychopharmacol, 1:361–373, 1991.
6.
BeiderbeckD, ReberS, HavasiA, BredewoldR, VeenemaA, NeumannI: High and abnormal forms of aggression in rats with extremes in trait anxiety–involvement of the dopamine system in the nucleus accumbens. Psychoneuroendocrinology, 37:1969–1980, 2012.
7.
BenjaminiY, HochbergY: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc, 57:289–300, 1995.
8.
BenjaminiY, HochbergY: On the adaptive control of the false discovery rate in multiple testing with independent statistics. J Educ Behav Stat, 25:60–83, 2000.
9.
BiedermanJ, FaraoneS, MickE. Attention-deficit and hyperactivity disorder and juvenile mania: An over-looked comorbidity?. J Am Acad Child Adolesc Psychiatry, 35:997–1008, 1996.
10.
BiedermanJ, MickE, FaraoneS, Van PattenS, BurbackM, WozniakJ: A prospective follow-up study of pediatric bipolar disorder in boys with attention-deficit/hyperactivity disorder. J Affect Disord, 82:S17–S23, 2004.
11.
Brawman–MintzerO, KnappR, NeitertP: Adjunctive risperidone in generalized anxiety disorder: A double-blind, placebo-controlled study. J Clin Psychiatry, 10:1321–1325, 2005.
12.
CoccaroE, McCloskeyM, FitzgeraldD, PhanK: Amygdala and orbitofrontal reactivity to social threat in individuals with impulsive aggression: Biol Psychiatry, 62:168–178, 2007.
13.
CoccaroE, SripadaC, YanowitchR, PhanK: Corticolimbic function in impulsive aggression behavior. Biol Psychiatry, 69:1153–1159, 2011.
14.
CraftM: Tranquilizers in mental deficiency: Meprobamate. J Ment Defic Res, 2:17–20, 1958.
15.
DodgeK: Emotion and social information processing. In: The Development of Emotion Regulation and Dysregulation, edited by GarberJ., and DodgeK.A.New York: Cambridge University Press, 159–181, 1991.
16.
DodgeK: Social cognition and children's aggressive behavior. Child Dev, 51:162–170, 1980.
17.
DodgeK, CoieJ: Social–information-processing factors in reactive and proactive aggression in children's peer groups. J Pers Soc Psychol, 53:1146–1158, 1987.
18.
DodgeK, LochmanJ, HarnishJ, BatesJ, PettitG: Reactive and proactive aggression in school children and psychiatrically impaired chronically assaultive youth. J Abnorm Psychol, 106:37–51, 1997.
19.
FarmerC, ArnoldL, BuksteinO, FindlingR, GadowK, LiX, ButterE, AmanM: The treatment of severe child aggression (TOSCA) study: Design challenges. Child Adolesc Psychiatry Ment Health, 5:1–11, 2011.
20.
GadowK: Schizophrenia spectrum and attention-deficit/hyperactivity disorder symptoms in autism spectrum disorder and controls. J Am Acad Child Adolesc Psychiatry, 51:1076–1084, 2012.
21.
GadowK, ArnoldL, MolinaS, FindlingR, BuksteinO, BrownN, McNamaraN, Rundberg–RiveraE, LiX, KippH, SchneiderJ, FarmerC, BakerJ, SprafkinJ, RiceR, BangaloreS, ButterE, Buchan–PageK, HurtE, AustinA, GrondhuisS. Risperidone added to parent training and stimulant medication: Effects on attention–deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression. J Am Acad Child Adolesc Psychiatry, 53:948–959, 2014.
22.
GadowKD, DrabickDAG: Anger and irritability symptoms among youth with ODD :Cross-informant vs. source-exclusive syndromes. J Abnorm Child Psychol, 40:107–1085, 2012.
GadowKD, SprafkinJ: The Symptom Inventories: An Annotated Bibliography. Stony Brook, NY: Checkmate Plus, 2013. Available at www.checkmateplus.com.
25.
GurkaM, EdwardsL, MullerK: Avoiding bias in mixed model interference for fixed effects. Stat Med, 30:2696–2707, 2011.
26.
HannaG, FluentT, FischerD: Separation anxiety in children and adolescents treated with risperidone. J Child Adolesc Psychopharmacology, 9:277–283, 1999.
27.
KaatA, GadowK, LecavalierL: Psychiatric symptom impairment in children with autism spectrum disorders. J Abnorm Child Psychol, 41:959–969, 2013.
28.
KashaniJ, DeuserW, ReidJ: Aggression and anxiety: A new look at an old notion. J Am Acad Child Adolesc Psychiatry, 30:218–223, 1991.
29.
KelleherI, JennerJ, CannonM: Psychotic symptoms in the general population: An evolutionary perspective. Br J Psychiatry, 197:167–169, 2010.
30.
KingB, LordC: Is schizophrenia on the autism spectrum?. Brain Res, 1380:34–41, 2011.
31.
KleinR, ManuzzaS, OlazagastiM, RoizenE, HutchinsonJ, LashuaE, CastellanosF: Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later: Arch Gen Psychiatry, 69:1295–303, 2012.
32.
KraemerH, WilsonG, FairburnC, AgrasW: Mediators and moderators of treatment effects in randomized clinical trials: Arch Gen Psychiatry, 59:877–883, 2002.
33.
LearyA, CollettB, MyersK: Rating Scales. In: Dulcan's textbook of child and adolescent psychiatry, edited by DulcanM.K.. Washington, DC: American Psychiatric Publishing; 2011. Pp. 89–110.
34.
LendeD: The Research Domain Criteria of the NIMH and the RDoC Vision for Mental Health Research and Diagnosis. Plos BlogsFebruary9, 2014. Available at http://blogs.plos.org/neuroanthropology/2014/02/09/research-domain-criteria-nimh-vision-mental-health-research-diagnosis/
35.
LuK: On efficiency of constrained longitudinal data analysis versus longitudinal analysis of covariance: Biometrics, 66:891–896, 2010.
36.
MarderSR, DavisJM, ChavinardG: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the N. American trials. J Clin Psychiatry, 58:538–546, 1997.
37.
MTA Cooperative Group: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder: Arch Gen Psychiatry, 56:1073–1086, 1999a.
38.
MTA Cooperative Group: Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: Arch Gen Psychiatry, 56:1088–1096, 1999b.
39.
NeumannI, VeenemaAH, BeiderbeckD: Aggression and anxiety: social context and neurobiological links Front. Behav Neurosci, 4:1–16, 2010.
40.
PadgettF, MiltsiouE, TiffinP: The co-occurrence of nonaffective psychosis and the pervasive developmental disorders: A systematic review. J Intellect Dev Disabil, 35:187–198, 2010.
41.
PandinaG, CanusoC, TurkozI, KujawaM, MahmoudR: Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial. Psychopharmacol Bull, 40:41–57, 2007.
42.
PandinaG, KujawaM, CanuscoC, Kosik–GonzalezC, TurkozI, GharabawiG: Adjunctive risperidone in the treatment of generalized anxiety disorder: A double- blind, placebo-controlled, randomized study. Int J Neuropsychopharmacol, 9: S119–S119, 2006.
43.
RavindranAV, BradburyC, McKayM, daSilvaTL: Novel uses for risperidone: Focus on depression, anxiety, and behavioral disorders. Expert Opin Pharmacother, 8:1693–1710, 2007.
44.
SahakianB, RobbinsT: Are the effects of psychomotor stimulant drugs on hyperactive children really paradoxical?. Med Hypotheses, 3:154–158, 1977.
45.
SAS Institute: SAS/GIS 9.2: Spatial Data and Procedure Guide. Cary, NC: SAS Institute, Inc.; 2009.
46.
SeoJ, JamiesonK, CosgroveV, GwizdowskiI, YangH, SheehanD, McElroyS, SuppesT: Characteristics of responders and non-responders to risperidone monotherapy or placebo in co-occurring bipolar disorder and anxiety disorder. Eur Psychiatry, 28:190–196, 2013.
47.
SheehanD, McElroyS, Harnett–SheehanK, KeckP, JanavsJ, RogersJ, GonzalezR, ShivakumarG, SuppesT: Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. J Affect Disord, 115:376-385, 2009.
48.
SimonN, HogeE, FischmannD, WorthingtonJ, ChristianK, KinrysG, PollackM: An open-label trial of risperidone augmentation for refractory anxiety disorders: J Clin Psychiatry, 67:381–385, 2006.
WaltersA, SinghN, BealeI: Effects of lorazepam on hyperactivity in retarded children: N Z Med J, 86:473–475, 1977.
51.
ZrullJ, WestmanJ, ArthurB, RiceD: A comparison of diazepam, d-amphetamine, and placebo in the treatment of hyperkinetic syndrome in children: Am J Psych, 121:388–389, 1964.
